Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk : Results from the EPIC cohort
(2018) In Cancer Epidemiology Biomarkers and Prevention 27(7). p.790-804- Abstract
Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression. Results: In controls, lower antibodies against both... (More)
Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression. Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both. Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types. Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC.
(Less)
- author
- organization
- publishing date
- 2018-07-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Epidemiology Biomarkers and Prevention
- volume
- 27
- issue
- 7
- pages
- 15 pages
- publisher
- American Association for Cancer Research
- external identifiers
-
- scopus:85049634585
- pmid:29661801
- ISSN
- 1055-9965
- DOI
- 10.1158/1055-9965.EPI-17-0744
- language
- English
- LU publication?
- yes
- id
- 6627370c-299c-43d1-90d3-0b380d7cbbf9
- date added to LUP
- 2018-07-23 14:23:04
- date last changed
- 2024-01-29 18:54:45
@article{6627370c-299c-43d1-90d3-0b380d7cbbf9,
abstract = {{<p>Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression. Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both. Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types. Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC.</p>}},
author = {{Cramer, Daniel W. and Fichorova, Raina N. and Terry, Kathryn L. and Yamamoto, Hidemi and Vitonis, Allison F. and Ardanaz, Eva and Aune, Dagfinn and Boeing, Heiner and Brandstedt, Jenny and Boutron-Ruault, Marie Christine and Chirlaque, Maria Dolores and Dorronsoro, Miren and Dossus, Laure and Duell, Eric J. and Gram, Inger T. and Gunter, Marc and Hansen, Louise and Idahl, Annika and Johnson, Theron and Khaw, Kay Tee and Krogh, Vittorio and Kvaskoff, Marina and Mattiello, Amalia and Matullo, Giuseppe and Merritt, Melissa A. and Nodin, Bjorn and Orfanos, Philippos and Onland-Moret, N. Charlotte and Palli, Domenico and Peppa, Eleni and Quiros, J. Ramon and Sanchez-Perez, Maria Jose and Severi, Gianluca and Tjønneland, Anne and Travis, Ruth C. and Trichopoulou, Antonia and Tumino, Rosario and Weiderpass, Elisabete and Fortner, Renee T. and Kaaks, Rudolf}},
issn = {{1055-9965}},
language = {{eng}},
month = {{07}},
number = {{7}},
pages = {{790--804}},
publisher = {{American Association for Cancer Research}},
series = {{Cancer Epidemiology Biomarkers and Prevention}},
title = {{Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk : Results from the EPIC cohort}},
url = {{http://dx.doi.org/10.1158/1055-9965.EPI-17-0744}},
doi = {{10.1158/1055-9965.EPI-17-0744}},
volume = {{27}},
year = {{2018}},
}